Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
| ▸ | BCHE | P06276 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | JAK1 | P23458 | 3/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596881 | 0.90 | FPR2 (0.42) | USP30FPR2HTR6BCHEJAK2 | |
| SCHEMBL5596618 | 0.87 | BRD4 (0.42) | USP30FPR2HTR6BCHEJAK2 | |
| SCHEMBL5597044 | 0.85 | SCN9A (0.42) | USP30FPR2HTR6BCHEHPGDS | |
| SCHEMBL5596748 | 0.85 | HTR6 (0.41) | USP30FPR2HTR6BCHEHPGDS | |
| SCHEMBL5596364 | 0.84 | TNF (0.40) | USP30FPR2HTR6BCHEHPGDS | |
| SCHEMBL5596791 | 0.84 | HPGDS (0.40) | USP30FPR2HTR6BCHEHPGDS | |
| SCHEMBL5596756 | 0.83 | HTR6 (0.40) | USP30FPR2HTR6BCHEHPGDS | |
| SCHEMBL5596624 | 0.83 | FGFR4 (0.41) | USP30FPR2HTR6BCHEJAK2 | |
| SCHEMBL5596980 | 0.81 | USP30 (0.42) | USP30FPR2HTR6BCHEHPGDS | |
| SCHEMBL5596780 | 0.80 | TNF (0.43) | USP30SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | USP30 3669/4885FPR2 3865/4885HTR6 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.